Austin Medical Technologies, Inc. Secures Six-Year Contract with Eagle Laboratories to Private Label Under the eyeDirecti Brand.

PLANO, Texas -- Austin Medical Technologies, Inc. (Pink Sheets:AMTK), partners with Eagle Laboratories as a key supplier of Single-Use Cannula, which are offered in all eyeDirecti Ophthalmic Surgical Packs. Our annual volume with Eagle has doubled two years consecutively.

AMTK is moving rapidly in the direction of strengthening the eyeDirecti "Brand" by private labeling of products. AMTK additionally has moved to an exclusive relationship with our drape manufacturer to private label custom ophthalmic drapes used in surgery. This move will improve our current gross profit by as much as 25%.

Kurt Tarter, President & CEO stated, "The six-year relationship with Eagle Labs has delivered significant value to our customers and allowed eyeDirecti to compete most effectively against our multi-billion dollar competitors."

Rich De Camp, Vice President of Eagle Labs stated, "Our reciprocating relationship with eyeDirecti has been mutually beneficial as it has helped our company to grow market share while delivering enhanced value to eyeDirecti's customers."

About Eagle Labs

Founded in 1988 by Dennis M. De Camp, Eagle Laboratories celebrates 15 years of continuous growth as a leading manufacturer of Single-Use Ophthalmic Products worldwide. Eagle's manufacturing facility is located in Rancho Cucamonga, Calif. Eagle Laboratories is now a leading source of Single-Use Ophthalmic Surgical Products. Eagle manufactures one of the largest selections of Ophthalmic Cannulae available today, to include a wide variety of Ophthalmic Products encompassing; Surgical Knives, Vitreoretinal Products, Ophthalmic Drapes, Fluid Administration Sets, I.V. Lines, Surgical Sponge Products, Products for LASIK, and products for Occuloplastic and Glaucoma Surgery. Eagle Laboratories guarantee their products are manufactured with the highest quality standards. Eagle Laboratories complies with the U.S. Food and Drug Administration. The Manufacturing facility is ISO 9001 Registered and all Eagle Products Carry the European Union CE Mark registration.

About Austin Medical Technologies, Inc./eyeDirecti(TM) (Brand)

Austin Medical Technologies delivers "DIRECT" from the manufacturer to the Surgeon, the only technology based, "Single Source Supply Solution" for custom sterile surgery trays made up of 80% of all disposable surgical devices utilized in surgery. Currently the company has contracted with 200 eye surgery centers including the 2 largest eye surgery centers in the USA. The market for custom sterile surgery trays is a $2.1 Billion market here in the USA.

Austin Medical is dedicated exclusively to the Ambulatory Surgery Center (ASC) market. Ambulatory Surgery Centers (ASC), also called outpatient surgery, and same-day surgery, refers to surgical procedures which are complex enough to require a dedicated operating room and specially trained staff, but do not require an overnight stay. According to 1996 U.S. government statistics, ambulatory surgery centers account for 31 million or 44% of the total surgeries performed in the United States. Five million surgeries were performed on eyes. New surgical techniques such as laser surgery allow procedures to be done more quickly and/or with less surgical trauma.

Under the brand name eyeDirecti, Austin Medical is initially focused on Ophthalmology owned and operated surgery centers which is the fastest growing segment of the ASC market, growing by 25% per annum, consisting of 2,500 practices with 15,000 surgeons performing over 5 million surgical procedures annually at a supply cost of $400 million per year. Austin Medical is positioned to capture $40 million (10%) of this $400 million market within the next 4 years. Visit our e-commerce site at www.eyedirecti.com

Note: Any statements released by Austin Medical Technologies, Inc, or any of its affiliates that are forward- looking, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the Company's business prospects and performances. These include economic, competitive, governmental, technological and other factors discussed in the statements and in the Company's filings with the Securities and Exchange Commission.